FDA Approves Alhemo for Patients with Hemophilia
Routine prophylaxis to prevent or reduce bleedingFor Patients with Hemophilia A or B with Inhibitors
The FDA has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with:
- Hemophilia A with factor VIII inhibitors, or
- Hemophilia B with factor IX inhibitors.
What It Is
- Alhemo is a subcutaneous (under the skin) injection, taken daily.
- It’s designed for patients who have developed inhibitors — antibodies that block standard clotting factor treatments.
Effectiveness
- In a global phase 3 trial, Alhemo reduced annual bleeding rates by 86% compared to no prophylaxis.
- Participants included 91 adults and 42 adolescents with hemophilia A or B, with inhibitors.
Safety Info
- Most common side effects: Injection site reactions and hives.
- May cause hypersensitivity (rash, itching, abdominal pain) and increased risk of blood clots.
- Not recommended for patients with serious allergies to the drug or its ingredients.
Special FDA Designations
- Priority Review
- Orphan Drug status (for rare conditions)
Alhemo offers a new preventative option for a high-risk hemophilia population where standard clotting therapies may fail.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
Exposure to toxic materials during hemodialysis and dialysis
FDA announcement The US Food and Drug Administration (FDA) issued an announcement on March 7 to update its May 2022 letter to healthcare providers regarding the potential risks of exposure to toxic compounds when using hemodialysis and peritoneal dialysis. This update...
FDA Breakthrough Devices Program
FDA Breakthrough Devices Program The U.S. Food and Drug Administration (FDA) has established the Breakthrough Devices Program, a voluntary program that aims to expedite the development, assessment, and review of medical devices that demonstrate potential to provide...
FDA Explores Dental Device Safety Concerns
Dental Devices to Treat Sleep Apnea and TMD The FDA is currently evaluating safety concerns related to certain dental devices called fixed (non-removable) palatal expanders, which are used on adults for jaw remodeling or to treat conditions like obstructive sleep...